Mazanti-Andersen advises Hemab as it raises USD 55 million Series A co-led by Novo Holdings 

Hemab, a Danish based biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, has raised USD 55 million in Series A funding. The round was co-led by Novo Holdings alongside HealthCap and RA Capital Management.  

Hemab was founded in 2020 by Johan Henrik Faber and Søren Bjørn. Proceeds from the financing will be used to progress Hemab’s promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development. The pipeline will initially focus on underserved people living with rare bleeding disorders such as Glanzmann’s Thrombasthenia (GT), with plans to expand into more common disorders of hemostasis and thrombosis. The financing will also enable Hemab to further build the team and expand its operations in Denmark and the US.

Mazanti Transactions advised Hemab in connection with all aspects of the investment.

Read more about Hemab and its recent investment round here and here.